The tumor microenvironment (TME) is a complex, dynamic battlefield for both immune cells
and tumor cells. The advent of the immune checkpoint inhibitors (ICI) since 2011, such as …

The development of cancer immunotherapies has been guided by advances in our
understanding of the dynamics between tumor cells and immune populations. An emerging …

Although recent cancer immunotherapy strategies, including immune-checkpoint blockade
(ie blocking PD-1, PD-L1 or CTLA-4), have shown durable clinical effects in some (but not …

Simple Summary Immunotherapy helps a person's immune system to target tumor cells.
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …

Over the last decade, our understanding of how cancer cells interact with their
microenvironment has grown exponentially. It has become evident that a complex interplay …

Dendritic cells (DCs) efficiently process and present antigens to T cells, and by integrating
environmental signals, link innate and adaptive immunity. DCs also control the balance …

Simple Summary High T-cell infiltration has been associated with improved clinical
outcomes in many human solid tumors. However, these cells are not autonomous in their …

The tumour microenvironment plays a dual role in cancer: it can promote tumour
progression by establishing pro‐tumour survival conditions but can also suppress tumour …

Immune checkpoints or coinhibitory receptors, such as cytotoxic T lymphocyte antigen
(CTLA)-4 and programmed death (PD)-1, play important roles in regulating T cell responses …

Cancers develop complex and dynamic tissue microenvironments to support their sustained
growth, invasion and metastasis. For decades, rapid progress has been made in the cross …